{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T19:37:40Z","timestamp":1765741060265,"version":"3.48.0"},"reference-count":29,"publisher":"BMJ","issue":"8","funder":[{"DOI":"10.13039\/100014554","name":"Janssen Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014554","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2017,7,19]]},"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To describe the minimal disease activity (MDA) rate over time in patients with psoriatic arthritis (PsA) receiving antitumour necrosis factor agents, evaluate prognostic factors of MDA achievement and identify the most common unmet criteria among MDA achievers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Biologic Treatment Registry Across Canada (BioTRAC): ongoing, prospective registry of patients initiating treatment for rheumatoid arthritis, ankylosing spondylitis or PsA with infliximab (IFX), golimumab (GLM) or ustekinumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>46 primary-care Canadian rheumatology practices.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>223 patients with PsA receiving IFX (enrolled since 2005) and GLM (enrolled since 2010) with available MDA information at baseline, 6 months and\/or 12 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>MDA was defined as \u22655 of the following criteria: 28-item tender joint count (TJC28) \u22641, 28-item swollen joint count (SJC28) \u22641, Psoriasis Area and Severity Index (PASI) \u22641 or body surface area\u22643, Pain Visual Analogue Scale (VAS) \u226415\u2009mm, patient\u2019s global assessment (PtGA) (VAS) \u226420\u2009mm, Health Assessment Questionnaire (HAQ) \u22640.5, tender entheseal points \u22641. Independent prognostic factors of MDA achievement were assessed with multivariate logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>MDA was achieved by 11.7% of patients at baseline, 43.5% at 6 months, 44.8% at 12 months and 48.8% at either 6 or 12 months. Among MDA achievers at 6 months, 75.7% had sustained MDA at 12 months. Lower baseline HAQ (OR=0.210; 95%\u2009CI: 0.099 to 0.447) and lower TJC28 (OR=0.880; 95%\u2009CI: 0.804 to 0.964), were significant prognostic factors of MDA achievement over 12 months of treatment. The most commonly unmet MDA criteria among MDA achievers was patient reported pain (25%), PtGA (15%) and PASI (12%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Almost 50% of patients treated with IFX or GLM in routine clinical care achieved MDA within the first year of treatment. Lower baseline HAQ and lower TJC28, were identified as significant prognostic factors of MDA achievement. The most commonly unmet criteria in patients who achieved MDA were pain, PtGA and PASI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      BioTRAC (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00741793\">NCT00741793<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2017-016619","type":"journal-article","created":{"date-parts":[[2017,8,30]],"date-time":"2017-08-30T20:25:27Z","timestamp":1504124727000},"page":"e016619","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":24,"title":["Real-world validation of the minimal disease activity index in psoriatic arthritis: an analysis from a prospective, observational, biological treatment registry"],"prefix":"10.1136","volume":"7","clinical-trial-number":[{"clinical-trial-number":"nct00741793","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Proton","family":"Rahman","sequence":"first","affiliation":[{"name":"Medicine, Memorial University of Newfoundland, St. Johns, Newfoundland, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Zummer","sequence":"additional","affiliation":[{"name":"Rheumatology, H\u00f4pital Maisonneuve-Rosemont, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Bessette","sequence":"additional","affiliation":[{"name":"Infectious and immune diseases, Centre Hospitalier de l'Universit\u00e9 Laval, Quebec City, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Baer","sequence":"additional","affiliation":[{"name":"Rheumatology, Ontario Medical Association, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boulos","family":"Haraoui","sequence":"additional","affiliation":[{"name":"Rheumatology, Centre Hospitalier de l\u2019 Universit\u00e9 de Montr\u00e9al, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Chow","sequence":"additional","affiliation":[{"name":"Rheumatology, Credit Valley Rheumatology, Mississauga, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Kelsall","sequence":"additional","affiliation":[{"name":"Rheumatology, Saint Paul's Hospital, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suneil","family":"Kapur","sequence":"additional","affiliation":[{"name":"Rheumatology, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanouil","family":"Rampakakis","sequence":"additional","affiliation":[{"name":"JSS Medical Research Inc., St-Laurent, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliofotisti","family":"Psaradellis","sequence":"additional","affiliation":[{"name":"JSS Medical Research Inc., St-Laurent, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allen J","family":"Lehman","sequence":"additional","affiliation":[{"name":"Janssen Inc., Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francois","family":"Nantel","sequence":"additional","affiliation":[{"name":"Janssen Inc., Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brendan","family":"Osborne","sequence":"additional","affiliation":[{"name":"Janssen Inc., Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathy","family":"Tkaczyk","sequence":"additional","affiliation":[{"name":"Janssen Inc., Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,8,30]]},"reference":[{"key":"2025121411343051000_7.8.e016619.1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/archopht.123.2.267","article-title":"Therapeutic neutrophil apheresis in patients with ocular Beh\u00e7et disease","volume":"123","author":"Sonoda","year":"2005","journal-title":"Arch Ophthalmol"},{"doi-asserted-by":"publisher","key":"2025121411343051000_7.8.e016619.2","DOI":"10.2310\/7750.2011.10101"},{"doi-asserted-by":"publisher","key":"2025121411343051000_7.8.e016619.3","DOI":"10.1093\/rheumatology\/keg384"},{"doi-asserted-by":"publisher","key":"2025121411343051000_7.8.e016619.4","DOI":"10.1093\/rheumatology\/keg217"},{"key":"2025121411343051000_7.8.e016619.5","first-page":"809","article-title":"Longitudinal study of clinical and radiological progression in psoriatic arthritis","volume":"17","author":"Gladman","year":"1990","journal-title":"J Rheumatol"},{"doi-asserted-by":"publisher","key":"2025121411343051000_7.8.e016619.6","DOI":"10.1002\/art.1780401021"},{"doi-asserted-by":"publisher","key":"2025121411343051000_7.8.e016619.7","DOI":"10.1002\/1529-0131(200104)45:2<151::AID-ANR168>3.0.CO;2-T"},{"doi-asserted-by":"publisher","key":"2025121411343051000_7.8.e016619.8","DOI":"10.1002\/art.22443"},{"doi-asserted-by":"publisher","key":"2025121411343051000_7.8.e016619.9","DOI":"10.1136\/ard.2004.032482"},{"doi-asserted-by":"publisher","key":"2025121411343051000_7.8.e016619.10","DOI":"10.1185\/03007990903185557"},{"doi-asserted-by":"publisher","key":"2025121411343051000_7.8.e016619.11","DOI":"10.1136\/ard.2009.123976"},{"unstructured":"National institute for health and clinical excellence. The management of rheumatoid arthritis in adults. 2009 http:\/\/www.nice.org.uk\/guidance\/cg79 (accessed 28 Mar 2016).","key":"2025121411343051000_7.8.e016619.12"},{"doi-asserted-by":"publisher","key":"2025121411343051000_7.8.e016619.13","DOI":"10.1002\/art.22379"},{"doi-asserted-by":"publisher","key":"2025121411343051000_7.8.e016619.14","DOI":"10.1002\/art.20335"},{"doi-asserted-by":"publisher","key":"2025121411343051000_7.8.e016619.15","DOI":"10.1002\/art.22805"},{"doi-asserted-by":"publisher","key":"2025121411343051000_7.8.e016619.16","DOI":"10.1136\/ard.2008.102053"},{"doi-asserted-by":"publisher","key":"2025121411343051000_7.8.e016619.17","DOI":"10.1002\/acr.20162"},{"doi-asserted-by":"publisher","key":"2025121411343051000_7.8.e016619.18","DOI":"10.1002\/acr.20155"},{"doi-asserted-by":"publisher","key":"2025121411343051000_7.8.e016619.19","DOI":"10.1016\/S0140-6736(15)00347-5"},{"key":"2025121411343051000_7.8.e016619.20","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/acr.22290","article-title":"Effectiveness and safety of infliximab in rheumatoid arthritis: analysis from a Canadian multicenter prospective observational registry","volume":"66","author":"Thorne","year":"2014","journal-title":"Arthritis Care Res"},{"doi-asserted-by":"publisher","key":"2025121411343051000_7.8.e016619.21","DOI":"10.3899\/jrheum.120970"},{"doi-asserted-by":"publisher","key":"2025121411343051000_7.8.e016619.22","DOI":"10.1002\/acr.22529"},{"doi-asserted-by":"publisher","key":"2025121411343051000_7.8.e016619.23","DOI":"10.3899\/jrheum.150595"},{"doi-asserted-by":"publisher","key":"2025121411343051000_7.8.e016619.24","DOI":"10.1136\/annrheumdis-2012-201972"},{"doi-asserted-by":"crossref","unstructured":"Kavanaugh A , van der Heijde D , Beutler A , et al . Patients with psoriatic arthritis who achieve minimal disease activity in response to golimumab therapy demonstrate less radiographic progression: Results through 5 years of the randomized, placebo-controlled, GO-REVEAL study. Arthritis Care Res 2015.","key":"2025121411343051000_7.8.e016619.25","DOI":"10.1002\/acr.22576"},{"doi-asserted-by":"publisher","key":"2025121411343051000_7.8.e016619.26","DOI":"10.3899\/jrheum.110763"},{"doi-asserted-by":"publisher","key":"2025121411343051000_7.8.e016619.27","DOI":"10.1186\/ar3021"},{"doi-asserted-by":"publisher","key":"2025121411343051000_7.8.e016619.28","DOI":"10.1093\/rheumatology\/keq091"},{"key":"2025121411343051000_7.8.e016619.29","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/acr.20161","article-title":"Measuring joint involvement in polyarticular psoriatic arthritis: an introduction of alternatives","volume":"62","author":"Englbrecht","year":"2010","journal-title":"Arthritis Care Res"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2017-016619","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T19:34:38Z","timestamp":1765740878000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2017-016619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":29,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,8,30]]},"published-print":{"date-parts":[[2017,8]]}},"alternative-id":["10.1136\/bmjopen-2017-016619"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2017-016619","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2017,8]]}}}